Articles On Dimerix (ASX:DXB)

ASX health sector falls in line with broader markets as macroeconomic factors continue to create volatility Dimerix soars on $230m licensing deal with ADVANZ PHARMA for DMX-200 into rare kidney disease US FDA approves Cyclofarm’s lung imag...

The S&P/ASX 200 Index (ASX: XJO) is on course to end the week on a positive note. In afternoon trade, the benchmark index is up 0.7% to 6,972.3 points. Four ASX shares that are rising more than most today are listed below. Here's why...

The Dimerix Ltd (ASX: DXB) share price is rising strongly for a second day in a row. So much so, at one stage today, the ASX healthcare share was up a further 48% to a 52-week high of 23 cents. When Dimerix's shares reached that level, it...

The Australian sharemarket rebounded from 11-month lows on Thursday, notching a small gain as markets braced for the official US jobs data on Friday night Australian time. The benchmark S&P/ASX 200 (INDEXASX: XJO) index gained 35.3 poin...

Benchmark index finds some rare greenage, up 0.5% Property and IT Sectors lead broad-based gains, XEC Emerging Co’s index now down 14% from July highs Fascinating small caps action: led by Dimerix, Bluglass and Experience Co.   The ASX2...

The ASX200 has broken its drought, managing to pick up half a per cent by the end of trade today.   Most sectors are in the green, with real estate the leader climbing two per cent. Those that struggled were energy, down nearly a per...

Stockhead’s In-Case-You-Missed-It highlights today’s most interesting small cap stories that might have slipped beneath your radar. Below is a wrap of the top 20 performing stocks, by percentage, who made announcements today.   ICYMI Leader...

On Thursday, the sharemarket experienced a rebound, influenced by a relief rally inspired by Wall Street. This rally was prompted by softer US jobs data, which temporarily alleviated concerns about high interest rates. However, the gains in...

  Dimerix partners with ADVANZ Pharma to commercialise DMX-200 for treatment of rare kidney disease Dimerix to receive up to ~AU$230 million in upfront and milestone payments, plus royalties ADVANZ to leverage its specialty, hospital, and...

Drug development company Dimerix (ASX: DXB) has secured a licencing deal with Advanz Pharma Corp for the commercialisation of Dimerix’s Phase 3 drug candidate DMX-200 to treat focal segmental glomerulosclerosis (FSGS) kidney disease. The ag...

In August, Australia's trade surplus expanded to $9.6 billion, surpassing expectations, as exports increased by 4 percent, primarily led by gold, while imports declined by 0.4 percent, largely due to a decrease in industrial transport equip...

05 Oct 2023 - A snapshot of the stocks on the move, featuring Vintage Energy (ASX:VEN), Rumble Resources (ASX:RTR), QX Resources (ASX:QXR), Dimerix (ASX:DXB) and BluGlass (ASX:BLG)…

  Vintage Energy (ASX:VEN) announces an additional two-year gas sale under the master gas supply agreement for the Odin gas field. The joint venture parties have agreed and signed terms with Pelican Point Power for the supply of gas from 1...

The Dimerix Ltd (ASX: DXB) share price has returned from its trading halt with a bang on Thursday. In morning trade, the ASX healthcare share was up a massive 130% to 14 cents. It has since pulled back but remains up an impressive 89% to 1...

Advanz Pharma and Dimerix (ASX:DXB) have announced they have entered into an exclusive license agreement for the European Economic Area, the UK, Switzerland, Canada, Australia, and New Zealand for the commercialisation of Dimerix’s...

Benchmark index falls to 11-month lows Utilities only sector in green Small caps led by Noxopharm   Local markets have extended unexpected October losses on Wednesday as tech stocks, and the Financial Sector led losses on another bond-...

ASX futures were down 0.51 per cent approaching 9:30 am AEDT after all major US bourses ended in the red overnight. It looks like the passing of September, notorious for being the worst month on the ASX at least, hasn’t hit the USA’s in...

L’Oréal to take minority stake in Chinese startup Shinehigh Innovation Shinehigh is developing supramolecular technology which could be used in the fashion industry Best and worst performing ASX biotechs over the past couple of weeks   Be...

Dimerix (ASX:DXB) has announced that the US FDA has given conditional approval for the brand name QYTOVRA for its Phase 3 clinical drug candidate.

FDA grants conditional approval for commercial brand name QYTOVRA Treatment targets billion-dollar market opportunity in rare FSGS kidney disease Treatment already has orphan drug designation Phase 3 clinical trial is progressing   The US...

Dimerix’s drug granted QYTOVRA as brand name by US FDA Starpharma completes recruitment for VIRALEZE study in UK Invion adds South Korea to list of exclusive territories for Photosoft    FDA says QYTOVRA can be used as DMX-200 brand name...

2023 a case of “haves and have nots” for ASX biotech sector as companies with good catalysts lead the pack  Neuren’s results of Phase 2 clinical trial of NNZ-2591 in Phelan-McDermid syndrome due in December Antisense Therapeutics Phase2b t...

The FDA has just approved an emergency use authorisation for new Covid-19 vaccines What is emergency use authorisation, and which ASX stocks have got it? We look at the best and worst performing ASX biotechs over the couple of weeks   On...

Stockhead’s In-Case-You-Missed-It highlights today’s most interesting small cap stories that might have slipped beneath your radar. Below is a wrap of the top 20 performing stocks, by percentage, who made announcements today.   ICYMI Leader...

Futures have predicted the ASX will open slightly lower today, driven by a mixed afternoon of trading on Wall Street and the underperformance of tech stocks. On home soil, today marks the eagerly awaited High Court decision that will det...

Earnings reports dominated headlines in August Despite solid results from ASX healthcare giants, the sector finished lower We take a look at which ASX healthcare stocks performed the best in August   August was all about earnings, and des...

Today we announce the fourth addition to our portfolio for 2021. Today we are adding Dimerix (ASX:DXB) to the Next Investors portfolio as our inaugural Biotech Pick of the Year for 2021.

Australian biotech has attracted US investments in the last five years Among ASX stocks to get funded from the US include Opthea We look at the  best and worst performing ASX biotechs over the past month   The Australian biotech sector co...

Neuren’s US FDA approval for trofinetide has seen its share price boosted ~130% in past year   Eye disease specialist Opthea is undertaking two Phase 3 trials to treat Wet AMD with results due in mid 2024 Anteris Technologies is developing...

Stockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have slipped your notice today.  It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentage terms...

Biotech could be a US$4 trillion industry in 10 years Genetic engineering and weight loss are two growing themes in the space We look at the best and worst performing ASX biotechs over the past month   Steve Jobs used to say that the most...

MoneyTalks is Stockhead’s regular drill down into what stocks investors are looking at right now. We’ll tap our extensive list of experts to hear what’s hot, their top picks, and what they’re looking out for. Today we hear from Peak Asset M...

Stockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have slipped your notice today.  It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentage terms...

Stockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have slipped your notice today.  It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentage terms...

Stockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have slipped your notice today.  It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentage terms...

Dimerix has achieved another key milestone in its ACTION 3 Focal Segmental Glomerulosclerosis (FSGS) trial with the Data  Safety Monitoring Board  (DSMB) safety review giving it the green light to continue as planned. Dimerix (ASX:DXB) has...

Dimerix (ASX:DXB) has announced that the independent Data Safety Monitoring Board has successfully concluded a second review of the ACTION3 phase 3 clinical trial.

The end of pandemic and higher rates have subdued biotech market But there are signs now the sector is making a comeback We take a look at the ASX Biotech Winners in July   The Covid-19 pandemic had produced windfalls for and attracted fa...

Stockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have slipped your notice today.  It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentage terms...

Stockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have slipped your notice today.  It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentage terms...

Dimerix (ASX:DXB) has confirmed that the first 72 patients have been randomised in its DMX-200 ACTION3 phase 3 trial in patients with FSGS kidney disease.

Stockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have slipped your notice today.  It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentage terms...

Dimerix has achieved a key milestone in its global Phase 3 Focal Segmental Glomerulosclerosis (FSGS) trial with the last patient of the first 72 patient cohort  now randomised, locking in a March 2024 date for interim outcome results.   Dim...

Futures suggest the ASX will open higher before the release of Australia’s inflation figures and the interest rate decisions from the Federal Reserve and ECB. Meanwhile, the Aussie dollar is down 0.7 per cent to 67.29 US cents. Here...

Stockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have slipped your notice today.  It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentage terms...

Peak Asset Management recently held its first Microcaps investor conference, and here’s what the punters and players had to say about it. In mid July, boutique firm Peak Asset Management organised its inaugural microcap investor conference,...

Stockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have slipped your notice today.  It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentage terms...

Stockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have slipped your notice today.  It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentage terms...

Stockhead’s In-Case-You-Missed-It highlights some strongest performing ASX stocks that might have slipped your notice today.  It’s a short, sharp update to help frame the trading day by showing some of the biggest movers in percentage terms...

Dimerix (ASX:DXB) has announced that the Paediatric Committee of the European Medicines Agency has accepted its Paediatric Investigation Plan for the development of DMX-200 for focal segmental glomerulosclerosis following the PDCO m...